ArticleAdvances in therapy2026
Effect of Elexacaftor/Tezacaftor/Ivacaftor Treatment on Extrapulmonary Complications of Cystic Fibrosis.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBenefits of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) therapy in people with cystic fibrosis (pwCF) may extend beyond the pulmonary system to extrapulmonary complications. This study compared extrapulmonary complication-related healthcare resource utilization (HCRU) prior to and following initiation of ELX/TEZ/IVA.
methodspwCF aged ≥ 6 years newly initiating ELX/TEZ/IVA on or after 10/21/2019 were identified in the Merative™ MarketScan
resultsThe study included 1612 pwCF. A relative reduction of 14.0% in the proportion of people with ≥ 1 extrapulmonary complication claim in any site of care was observed from the pre- to post-treatment period [1209 (75.0%) to 1040 (64.5%), p < 0.001]. Within the inpatient setting, a relative reduction of 64.2% in the proportion of patients with ≥ 1 extrapulmonary complication-related hospitalization was observed [397 (24.6%) pre-treatment to 142 (8.8%) post-treatment, p < 0.001]. The relative reductions in the proportion of people with ≥ 1 claim in any site of care were significant for four of the seven extrapulmonary systems [electrolyte (41.2%), upper respiratory (32.8%), nutritional (28.1%), and lower gastrointestinal (17.8%), all p < 0.001]; relative reductions in the inpatient setting were significant for six of the seven extrapulmonary systems [nutritional (77.2%), lower gastrointestinal (67.3%), upper gastrointestinal (63.9%), upper respiratory (62.9%), cystic fibrosis-related diabetes (57.1%), and electrolyte (39.7%), all p < 0.01].
conclusionsELX/TEZ/IVA significantly reduced extrapulmonary complication-related HCRU in CF. Findings suggest a multisystemic benefit of ELX/TEZ/IVA treatment in addition to demonstrated transformational benefits on pulmonary function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.